Source link : https://www.newshealth.biz/health-news/testing-elacestrant-with-other-targeted-drugs-for-metastatic-breast-cancer/
Findings from the phase Ib/II ELEVATE trial presented at the San Antonio Breast Cancer Symposium demonstrated the potential of the oral selective estrogen receptor degrader elacestrant (Orserdu) in combination with various targeted agents — including abemaciclib (Verzenio), palbociclib (Ibrance), and everolimus — for the treatment of metastatic breast cancer. In this exclusive MedPage Today video, […]
Author : News Health
Publish date : 2024-12-27 14:52:29
Copyright for syndicated content belongs to the linked Source.